Low expression of SHP-2 is associated with less favorable prostate cancer outcomes

Tumor Biology

Volumn 34, Issue 2, 2013, Pages 637-642

  Tassidis, Helena ^a   Brokken, Leon J S ^a   Jirström, Karin ^b   Bjartell, Anders ^c   Ulmert, David ^c,d   Härkönen, Pirkko ^a,e   Wingren, Anette Gjörloff ^a,f  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e UNIVERSITY OF TURKU   (Finland)

^f MALMÖ UNIVERSITY   (Sweden)

Author keywords

Prostate cancer; Src homology 2 domain containing tyrosine phosphatase 2 (SHP 2); Tissue microarray (TMA)

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; PROTEIN TYROSINE PHOSPHATASE SHP 2; PTPN11 PROTEIN, HUMAN;

ARTICLE; CANCER CELL; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CELL NUCLEUS; CONTROLLED STUDY; CYTOPLASM; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; NONHUMAN; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE SIZE; PROSTATECTOMY; PROTEIN EXPRESSION; PROTEIN FUNCTION; TISSUE MICROARRAY; AGED; CANCER STAGING; DISEASE COURSE; ENZYME IMMUNOASSAY; FOLLOW UP; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PHOSPHORYLATION; PROGNOSIS; PROSTATE TUMOR; SIGNAL TRANSDUCTION; STROMA CELL; SURVIVAL RATE; TUMOR CELL CULTURE;

AGED; CYTOPLASM; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NEOPLASM STAGING; PHOSPHORYLATION; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; SIGNAL TRANSDUCTION; STROMAL CELLS; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TUMOR CELLS, CULTURED;

MLCS; MLOWN;

EID: 84877110354     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-012-0590-1     Document Type: Article

References (19)

1. Culig Z, Bartsch G, Hobisch A. Interleukin-6 regulates androgen receptor activity and prostate cancer cell growth. Mol Cell Endocrinol. 2002;197:231-8.
2. Pilat MJ, Kamradt JM, Pienta KJ. Hormone resistance in prostate cancer. Cancer Metastasis Rev. 1998;17:373-81.
3. Chatterjee B. The role of the androgen receptor in the development of prostatic hyperplasia and prostate cancer. Mol Cell Biochem. 2003;253:89-101.
4. Matsuda T, Junicho A, Yamamoto T, et al. Cross-talk between signal transducer and activator of transcription 3 and androgen receptor signaling in prostate carcinoma cells. Biochem Biophys Res Commun. 2001;283:179-87.
5. Mustelin T, Vang T, Bottini N. Protein tyrosine phosphatases and the immune response. Nat Rev Immunol. 2005;5:43-57.
6. Tassidis H, Brokken LJ, Jirstrom K, et al. Immunohistochemical detection of tyrosine phosphatase SHP-1 predicts outcome after radical prostatectomy for localized prostate cancer. Int J Cancer. 2010;126:2296-307.
7. Neel BG, Gu H, Pao L. The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem Sci. 2003;28:284-93.
8. Chong ZZ, Maiese K. The Src homology 2 domain tyrosine phosphatases SHP-1 and SHP-2: diversified control of cell growth, inflammation, and injury. Histol Histopathol. 2007;22:1251-67.
9. Matozaki T, Murata Y, Saito Y, Okazawa H, Ohnishi H. Protein tyrosine phosphatase SHP-2: a proto-oncogene product that promotes Ras activation. Cancer Sci. 2009;100:1786-93.
10. Vantler M, Huntgeburth M, Caglayan E, Ten Freyhaus H, Schnabel P, Rosenkranz S. PI3-kinase/Akt-dependent antiapoptotic signaling by the PDGF alpha receptor is negatively regulated by Src family kinases. FEBS Lett. 2006;580:6769-76.
11. Yuan L, Yu WM, Xu M, Qu CK. SHP-2 phosphatase regulates DNA damage-induced apoptosis and G2/M arrest in catalytically dependent and independent manners, respectively. J Biol Chem. 2005;280:42701-6.
12. Chen J, Yu WM, Bunting KD, Qu CK. A negative role of SHP-2 tyrosine phosphatase in growth factor-dependent hematopoietic cell survival. Oncogene. 2004;23:3659-69.
13. Hobisch A, Ramoner R, Fuchs D, et al. Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype. Clin Cancer Res. 2001;7:2941-8.
14. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998;4:844-7.
15. Chan G, Kalaitzidis D, Neel BG. The tyrosine phosphatase Shp2 (PTPN11) in cancer. Cancer Metastasis Rev. 2008;27:179-92.
16. Xu R, Yu Y, Zheng S, et al. Overexpression of Shp2 tyrosine phosphatase is implicated in leukemogenesis in adult human leukemia. Blood. 2005;106:3142-9.
17. Chughtai N, Schimchowitsch S, Lebrun JJ, Ali S. Prolactin induces SHP-2 association with Stat5, nuclear translocation, and binding to the beta-casein gene promoter in mammary cells. J Biol Chem. 2002;277:31107-14.
18. Fridberg M, Kjellstrom S, Anagnostaki L, et al. Immunohistochemical: analyses of phosphatases in childhood B-cell lymphoma lower expression of PTEN and HePTP and higher number of positive cells for nuclear SHP2 in B-cell lymphoma cases compared to controls. Pediatr Hematol Oncol. 2008;25:528-40.
19. Jakob S, Schroeder P, Lukosz M, et al. Nuclear protein tyrosine phosphatase Shp-2 is one important negative regulator of nuclear export of telomerase reverse transcriptase. J Biol Chem. 2008;28:33155-61.